Kymera Therapeutics

Forecast & Rating23 analysts currently cover Kymera Therapeutics, with about 91.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $138.64, about 20.3% upside from the current price of $115.29. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 32.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Kymera Therapeutics closely still see room for the stock to rise. Data as of Sep 23, 2026; for reference only and not investment advice.